BRPI0508254A - methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents - Google Patents

methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Info

Publication number
BRPI0508254A
BRPI0508254A BRPI0508254-4A BRPI0508254A BRPI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A
Authority
BR
Brazil
Prior art keywords
compositions
cox
combination
psychiatric disorders
treating
Prior art date
Application number
BRPI0508254-4A
Other languages
Portuguese (pt)
Inventor
Diane Stephenson
Duncan P Taylor
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0508254A publication Critical patent/BRPI0508254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

MéTODOS E COMPOSIçõES PARA O TRATAMENTO OU PREVENçãO DE DISTúRBIOS PSIQUIáTRICOS COM INIBIDORES DE COX-2 SOZINHOS E EM COMBINAçãO COM AGENTES ANTIDEPRESSIVOS A presente invenção se refere a um método inédito de tratamento e/ou prevenção de distúrbios psiquiátricos em um paciente pela administração ao paciente de pelo menos um inibidor de Cox-2, sozinho ou em combinação com um ou mais agentes antidepressivos. São também descritas composições, composições farmacêuticas e kits.METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PSYCHIATRIC DISORDERS WITH ALONE COX-2 INHIBITORS AND IN COMBINATION WITH ANTIDEPRESSIVE AGENTS The present invention relates to a novel method of treating and / or preventing psychiatric disorders in a patient by administering a patient to a patient. at least one Cox-2 inhibitor, alone or in combination with one or more antidepressant agents. Compositions, pharmaceutical compositions and kits are also described.

BRPI0508254-4A 2004-03-02 2005-03-02 methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents BRPI0508254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54928104P 2004-03-02 2004-03-02
PCT/US2005/006818 WO2005084654A2 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Publications (1)

Publication Number Publication Date
BRPI0508254A true BRPI0508254A (en) 2007-07-24

Family

ID=34919463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508254-4A BRPI0508254A (en) 2004-03-02 2005-03-02 methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Country Status (5)

Country Link
EP (1) EP1725222A2 (en)
JP (1) JP2007526328A (en)
BR (1) BRPI0508254A (en)
CA (1) CA2556380A1 (en)
WO (1) WO2005084654A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2403039C2 (en) * 2004-10-15 2010-11-10 H.B.Opганон Treatment of bipolar disorders and accompanying symptoms
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
DE502007002185D1 (en) 2006-04-04 2010-01-14 Emodys Gmbh USES OF COMPOSITIONS CONTAINING KAPPA OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
AU2008331868B2 (en) 2007-11-28 2015-02-12 Nektar Therapeutics Oligomer-tricyclic conjugates
FR2935611B1 (en) * 2008-09-10 2010-10-15 Commissariat Energie Atomique USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
TW201322979A (en) * 2011-10-18 2013-06-16 Raqualia Pharma Inc Pharmaceutical composition
WO2013179153A1 (en) * 2012-05-10 2013-12-05 Mahesh Kandula Compositions and methods for treatment of neurological degenerative disorders and neurological diseases
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
WO2017213977A1 (en) * 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
MX2019015150A (en) 2017-06-30 2020-08-13 Chase Therapeutics Corp Nk-1 antagonist compositions and methods for use in treating depression.
WO2019060729A1 (en) * 2017-09-21 2019-03-28 Tremeau Pharmaceutials, Inc. An ingestible product and a method of using the same
MX2020005517A (en) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Crystal forms and production methods thereof.
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
BR112020026099A2 (en) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag transdermal therapeutic system containing asenapine
KR20220018004A (en) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 Controlled release formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452642T1 (en) * 2001-06-19 2010-01-15 Norbert Mueller USE OF COX-2 INHIBITORS TO TREAT AFFECTIVE DISORDERS

Also Published As

Publication number Publication date
WO2005084654A2 (en) 2005-09-15
CA2556380A1 (en) 2005-09-15
JP2007526328A (en) 2007-09-13
WO2005084654A3 (en) 2005-11-17
EP1725222A2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
CY1120961T1 (en) ORAL DOSAGE CONTAINERS INCLUDING ANTI-PETROLEUM PATENT AND ACID INHIBITOR
MX2020007092A (en) Methods of using ehmt2 inhibitors in treating or preventing blood disorders.
BRPI0408902A (en) selective cyclooxygenase-2 inhibitor compositions and 5-ht 1b / 1d agonists for the treatment and prevention of migraine
BR0304648A (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
NI200900106A (en) INHIBITORS OF THE ACTIVITY OF THE AKT.
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
CL2008001782A1 (en) Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
DE602006013191D1 (en) SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXYLIC ACIDS ARE EFFECTIVE PARP INHIBITORS
EA201270184A1 (en) TREATMENT OF LIVER DISORDERS PI3K INHIBITORS
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes
EA200800755A1 (en) IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS
BRPI0716069A2 (en) compound, pharmaceutical composition, and method for treating a disorder
ES2571730T3 (en) Pharmaceutical compositions comprising droxidopa
NO20083836L (en) N hydroksyakrylamidforbindelser
BR112021017350A2 (en) Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CL2009000803A1 (en) Use of a pegylated variant of igf-1 to treat, prevent a neuromuscular disorder; method for the treatment, prevention and / or delay of a neuromuscular disorder; composition comprising the modified igf-1 variant
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EA200800766A1 (en) PI3K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
TW200507840A (en) Method of treating multiple myeloma
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
AR053928A1 (en) REACTIVE METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
NO20091495L (en) Pyrazolopyrimidinderivat

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.